Page 6 - Nifty Pharma

Nifty Pharma, FMCG indices trading near key resistance zone

According to Ravi Nathani, an independent technical analyst, the Nifty FMCG index is expected to face resistance around 52,250 - 52,375 range; and the Pharma index at 13,425.

Nifty Pharma index may correct in near-term, downside target seen at 12,700

The Nifty Pharma Index is currently trading at a CMP of 12,976.80. The index is expected to undergo a consolidation phase with a negative bias

Nifty Pharma likely to weaken in near-term; adopt sell on rise approach

Nifty Pharma is weak on hourly charts. Traders should be cautious and sell on every rise, while Nifty Energy Index is in a range-bound phase, says Ravi Nathani

Nifty Realty chart indicates likely trend reversal, may slip up to 415

Meanwhile, the Nifty Pharma chart too is flashing caution signal for traders as it too could reverse, says Ravi Nathani, an independent technical analyst.

Nifty Pharma index looks weak on charts; support at 11,700-11,800 levels

Sell the Nifty Pharma index and its constituents and book profits, as the index has been underperforming in recent days

Nifty Pharma likely to remain bearish in near-term, can dip below 12,000

Meanwhile, charts suggest that Nifty Realty and Media indices are experiencing a phase of consolidation says Ravi Nathani, an independent technical analyst.

Charts exhibit bearish trend for Nifty Realty, Pharma indices in near-term

By booking profits and staying away from the market, investors can avoid potential losses and capitalise on future price fluctuations that may occur, said the technical analyst

Here's what the charts suggest for Nifty Realty, Media, Pharma indices

According to Ravi Nathani, an independent technical analyst, one should look to book profits in Nifty Realty either at current levels or on rally.

Can the rally in Nifty Realty index sustain? Here's what charts suggest

The Nifty Realty Index could face stiff resistance in the range of 445 to 457 levels.

Chart check: Buy the dips in Nifty Pharma, Sell the rallies in Nifty FMCG

The near-term trend is displaying a bullish bias for the Nifty Pharma index

Traders can adopt 'buy-on-dips' strategy for Nifty Media: Ravi Nathani

According to the technical analyst, the Nifty Media Index is currently displaying a range-bound pattern, with fluctuations occurring within a prescribed range

Charts suggest near-term upside for pharma, oil & gas shares: Ravi Nathani

According to the technical analyst, he remains bullish on Nifty Pharma, and Nifty Oil & Gas indices

Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 observations and adverse outcomes

Charts signal bearish trend for Nifty Pharma in near-term: Ravi Nathani

According to the technical analyst, traders must adopt 'sell-on-rise' strategy for Nifty Pharma, Nifty Energy, and Nifty Midcap 100 indices

Analysts turn cautious on Cipla as US FDA action delays key US launches

Analysts believe that some of the recent observations from the US FDA are critical in nature and could lead to a potential Official Action Indicated (OAI) classification for the Indore plant

Nifty IT, Realty indices look bullish on chart: Ravi Nathani

The technical analyst also expects a pullback in the Nifty Pharma index.

Ravi Nathani recommends to focus on realty, pharma shares on dips

The technical analyst also advices to avoid media stocks for now, as the Nifty Media index could side to 1,631 level.

Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

Here's why Ravi Nathani is bullish on realty, pharma shares over near-term

According to the technical analyst, charts suggest bullish trend for Nifty Pharma, Nifty Realty, and Nifty Media indices

Stay selective on defensives amid current market volatility: Analysts

Given the uncertainty on how the market trajectory may play out ahead, analysts believe investors can rotate allocation from high beta stocks to defensive plays albeit selectively